Island Pharmaceuticals Ltd · ASX:ILA
Island Pharmaceuticals — Investor Presentation (June 2024)
27 slides from Island Pharmaceuticals's investor presentation, Jun 3, 2024
Slide 1: ASX Announcement: Island presentation for Australian investor roadshow
3 June 2024 ASX Announcement Island presentation for Australian investor roadshow MELBOURNE Australia, 3 June 2024: Australian antiviral drug development company, Island Pharmaceuticals Ltd (ASX: ILA; “Island”; “the Company”) is pleased to release a copy of the presentation that will be delivered by
Slide 2: Priority Review Voucher and shareholder information
If ISLA-101 achieves FDA approval, and certain other criteria are met, Island may be eligible to obtain a "Priority Review Voucher" at the time of FDA approval. This means that as well as getting approval to manufacture and sell ISLA-101, the Priority Review Voucher (PRV) could permit Island to expe
Slide 3: Combatting Urgent Viral Disease Threats with a Key Focus on Dengue Fever
COMBATTING URGENT VIRAL DISEASE THREATS WITH A KEY FOCUS ON DENGUE FEVER JUNE 2024 (ASX: ILA) ISLAND PHARMACEUTICALS 1 JUNE 2024
Slide 4: Disclaimer
DISCLAIMER This presentation has been prepared by Island Pharmaceuticals Limited (ABN 641 183 842) (Company or Future performance Island Pharmaceuticals). This presentation contains certain "forward-looking statements". The words "expect", "anticipate", Not an offer or financial product advice "esti
Slide 5: Island Pharmaceuticals is an antiviral therapeutics company
Island Pharmaceuticals (ASX: ILA) is an antiviral therapeutics company targeting infectious diseases ISLAND PHARMACEUTICALS 3 JUNE 2024
Slide 6: Investment Highlights
INVESTMENT HIGHLIGHTS Addressing a Lead product ISLA-101 targeting dengue fever (lead indication) with further potential across a range of other high unmet need mosquito-borne viruses: Zika, yellow fever and Chikungunya. Significant market Dengue fever infects up to 400m per year.* Endemic in >100 c
Slide 7: About half of the world's population is now at risk of dengue
“About half of the world's population is now at risk of dengue with an estimated 100–400 million infections occurring each year” World Health Organisation, 30 May 2024 ISLAND PHARMACEUTICALS 5 JUNE 2024
Slide 8: Dengue is Close to Home
DENGUE IS CLOSE TO HOME Source 1 Source 2 Source 3 Source 4 Article sources: 1. https://www.news.com.au/travel/travel-updates/travel-stories/deadly-viral-infection-doubles-in-popular-tourists-spots- for-aussies/news-story/fc32fa4fc37ee1ed4ca48a4deb44f51c 2. https://shorturl.at/NsvwY 3. https://www.n
Slide 9: Dengue is a Widespread Issue
DENGUE IS A WIDESPREAD ISSUE Dengue outbreaks occurred in many countries of the world in the Americas, Africa, the Middle East, Asia, and the Pacific Islands HealthMap: recent reports of local or imported dengue cases https://www.healthmap.org/dengue/en - visited May 30, 2024 ISLAND PHARMACEUTICALS
Slide 10: Dengue in 2050 – A Global Disease
DENGUE IN 2050 – A GLOBAL DISEASE Prediction based on projections of future temperatures, rainfall, and mosquito populations Europe USA Australia NASA Earth Observatory map by Lauren Dauphin based on data from Janey Messina, University of Oxford - https://earthobservatory.nasa.gov/features/disease-v
Slide 11: Infection and Spread
INFECTION AND SPREAD Why the surge in dengue infections? Uninfected mosquito Warmer temperatures • Accelerate development • Increase activity of female mosquitoes • Reduce incubation time for mosquito to become Mosquito bites infectious 1-14 day How dengue infected person • Allow mosquitoes to incub
Slide 12: Dengue Can Be Lethal if Not Managed on Time
DENGUE CAN BE LETHAL IF NOT MANAGED ON TIME It directly impacts both white blood cell count and platelets, which are vital for body protective mechanisms Moderate symptoms: • Headache • High fever • Pain behind the • Rashes eyes • Muscle pain • Nausea • Flu-like symptoms • Vomiting • Joint and muscl
Slide 13: Commercial Opportunity
COMMERCIAL OPPORTUNITY ISLA-101 has potential as both a prophylactic and therapeutic Travelers Military National Outbreaks Malaria is also a mosquito Relationship with US Army in Millions of patients in Latin borne disease and therefore a place for Phase 2 study America offer potential for proxy for
Slide 14: About ISLA-101
About ISLA-101 ISLAND PHARMACEUTICALS 12 JUNE 2024
Slide 15: ISLA-101 Broad Activity Evident
ISLA-101 BROAD ACTIVITY EVIDENT Demonstrated activity against flaviviruses (a subgroup of arboviruses) in multiple models of infection • In in-vitro models ISLA-101 has demonstrated broad anti-viral activity Dengue • In in-vitro models using fresh human cells, ISLA-101 has 1-4 demonstrated potent an
Slide 16: ISLA-101 Prevents Viral Replication
ISLA-101 PREVENTS VIRAL REPLICATION Mechanism of action (how it works) ISLA-101 reduces viral load1 ISLA-101 inhibits propagation of flaviviruses Above: dose response showing ISLA-101’s ability to protect against dengue infection • To replicate, the virus needs to hijack the nucleus of the host cell
Slide 17: ISLA-101 Prevents Animal Deaths from Lethal Dengue
ISLA-101 PREVENTS ANIMAL DEATHS FROM LETHAL DENGUE ISLA-101 has also been shown to be protective in animal models of both dengue and Zika Virus. Two doses of ISLA-101 prevent 70% of deaths by otherwise lethal dengue Survival curve showing protection from lethal dengue challenge by increasing dose of
Slide 18: Single Ascending Dose Study Data Achieves Endpoints, Confirms Phase 2 Plan
SINGLE ASCENDING DOSE STUDY DATA ACHIEVES ENDPOINTS, CONFIRMS PHASE 2 PLAN • Island completed a 24-subject Single Ascending Dose study for ISLA-101 in early 2024, with highly positive outcomes: Data modelling predicts 300 mg/m2 ISLA-101 was safe and well tolerated twice daily dose for Phase 2 stud
Slide 19: ISLA-101 Development Milestones
ISLA-101 DEVELOPMENT MILESTONES • With data from the Single Ascending Dose study in hand, Island now plans to interact with the US FDA regarding the study outcomes and strategies for how to maximise the data obtained from the Phase 2 study • Plan is to incorporate a proposed therapeutic arm into the
Slide 20: Why Target Dengue First?
WHY TARGET DENGUE FIRST? Significant unmet need for disease with increasing incidence ISLAND PHARMACEUTICALS 18 JUNE 2024
Slide 21: Limited Solutions
LIMITED SOLUTIONS Dengue West Nile Zika Virus Yellow Japanese Comments fever Fever encephalitis Worldwide 400 million n/a Up to 1.5 130,000 70,000 Viral diseases are a leading cause of prevalence million hospitalization and death Effective No No No No No Other drugs have been explored in drug clinic
Slide 22: Building Our Pipeline
BUILDING OUR PIPELINE • In addition to ISLA-101, Island is exploring the acquisition or in-licensing of new drug candidates • Specific screening and scoring criteria being applied, based in part on the following criteria: • small molecule program • anti-viral • eligible for a Priority Review Voucher
Slide 23: Corporate Snapshot
CORPORATE SNAPSHOT Key data Recent ILA trading history Share price (AUD1) $0.075 Market cap1 $8.59m Shares on issue1 114,536,544 Options with 31,746,700 piggy-back right2 Cash3 $1.6m Board of Directors Substantial shareholders Ownership breakdown Dr Paul MacLeman, Executive Chairman Shareholder Owne
Slide 24: Scientific Advisory Board
SCIENTIFIC ADVISORY BOARD Dr Leigh Farrell Prof Stephen Thomas MD Dr Amy Patick Leigh has over 30 years’ experience in the Professor Stephen Thomas, MD has an international Amy Patick is a scientific consultant with deep biotechnology and pharmaceutical industry and is leadership role as Lead Princi
Slide 25: Upcoming Milestones
UPCOMING MILESTONES** H1 FY 2024 (Jul – Dec 2023; H1 FY 2025 (Jul – Dec H2 FY 2024 (Jan – Jun 2024) H2 FY 2025 (Jan – Jun 2025) Completed) 2024) • Key US and Australian • Dose final Single • Initiate Phase 2 trial • Data readout from patents granted for ISLA-101 Ascending Dose study Phase 2 study su
Slide 26: Recap: Filling a Fast-Growing Unmet Need
RECAP: FILLING A FAST-GROWING UNMET NEED Addressing a Lead product ISLA-101 targeting dengue fever (lead indication) with further potential across a range of other high unmet need mosquito-borne viruses: Zika, yellow fever and Chikungunya. Significant market Dengue fever infects up to 400m per year.
Slide 27: Island Pharmaceuticals (ASX: ILA)
Island Pharmaceuticals (ASX: ILA) islandpharmaceuticals.com @IslandPharma Island Pharmaceuticals ISLAND PHARMACEUTICALS 25 JUNE 2024
Island Pharmaceuticals — Investor Presentation (June 2024) on 6ix